BioDelivery +8.6% AH; FDA approves Bunavail


The FDA has approved BioDelivery's (BDSI) Bunavail for the "maintenance treatment of opioid dependence." The drug is expected to launch late in Q3.

BioDelivery estimates peak U.S. sales potential of up to $250M. A deal has been reached with Ashfield Market Access to "provide managed markets and trade support" for Bunavail.

From other sites
Comments (1)
  • airborne44
    , contributor
    Comment (1) | Send Message
     
    Anything since July 7th with their meeting with the FDA???
    Something has to happen???
    4 Aug 2014, 02:32 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs